Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Kyverna Therapeutics, Inc. (KYTX) had Debt to Capital Ratio of 0.11 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-39.73M |
|
-- |
|
-- |
|
$41.37M |
|
$-41.37M |
|
$1.64M |
|
$-39.73M |
|
$-39.73M |
|
$-39.73M |
|
$-39.73M |
|
$-39.73M |
|
$-39.73M |
|
$-41.37M |
|
$-41.02M |
|
60.43M |
|
60.43M |
|
$-0.66 |
|
$-0.66 |
|
| Balance Sheet Financials | |
$241.73M |
|
$1.34M |
|
$15.30M |
|
$257.02M |
|
$29.67M |
|
$24.81M |
|
$31.77M |
|
$61.44M |
|
$195.58M |
|
$195.58M |
|
$195.58M |
|
60.53M |
|
| Cash Flow Statement Financials | |
$-41.60M |
|
$-50.20M |
|
$-0.10M |
|
$124.64M |
|
$32.74M |
|
$-91.90M |
|
$3.17M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.15 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
0.11 |
0.13 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-41.60M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-20.31% |
|
-20.31% |
|
-15.46% |
|
-18.03% |
|
$3.23 |
|
$-0.69 |
|
$-0.69 |
|